Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 7 | 2021 | 32 | 2.870 |
Why?
|
| Liver Transplantation | 6 | 2023 | 89 | 2.850 |
Why?
|
| Hepatitis C, Chronic | 7 | 2021 | 21 | 2.820 |
Why?
|
| Antiviral Agents | 8 | 2021 | 50 | 2.320 |
Why?
|
| Liver Diseases | 3 | 2022 | 24 | 2.170 |
Why?
|
| Hepacivirus | 6 | 2021 | 15 | 1.580 |
Why?
|
| Coinfection | 3 | 2023 | 20 | 1.140 |
Why?
|
| Pregnancy Complications | 3 | 2022 | 45 | 1.070 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.040 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 3 | 0.930 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.860 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 34 | 0.770 |
Why?
|
| HIV Infections | 3 | 2021 | 466 | 0.740 |
Why?
|
| Societies, Medical | 1 | 2022 | 121 | 0.730 |
Why?
|
| Prejudice | 1 | 2021 | 34 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 111 | 0.690 |
Why?
|
| Patient Selection | 1 | 2021 | 194 | 0.680 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 119 | 0.670 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.630 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 7 | 0.630 |
Why?
|
| Humans | 20 | 2024 | 27072 | 0.620 |
Why?
|
| Quinoxalines | 1 | 2018 | 2 | 0.610 |
Why?
|
| Benzimidazoles | 1 | 2018 | 6 | 0.600 |
Why?
|
| Obesity | 1 | 2021 | 311 | 0.600 |
Why?
|
| Sulfonamides | 1 | 2018 | 37 | 0.600 |
Why?
|
| Fear | 1 | 2018 | 46 | 0.590 |
Why?
|
| Liver Cirrhosis | 5 | 2024 | 37 | 0.590 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.530 |
Why?
|
| Virology | 1 | 2015 | 2 | 0.500 |
Why?
|
| United States | 5 | 2022 | 2035 | 0.470 |
Why?
|
| Pregnancy | 3 | 2022 | 336 | 0.470 |
Why?
|
| Liver Function Tests | 2 | 2022 | 20 | 0.360 |
Why?
|
| Female | 8 | 2024 | 15212 | 0.350 |
Why?
|
| Drug Resistance, Viral | 3 | 2017 | 13 | 0.300 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 161 | 0.290 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 158 | 0.270 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 5 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 15 | 0.210 |
Why?
|
| Cost of Illness | 1 | 2023 | 50 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 33 | 0.210 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2022 | 31 | 0.200 |
Why?
|
| Sustained Virologic Response | 1 | 2021 | 1 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Prevalence | 1 | 2023 | 443 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 97 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2019 | 3485 | 0.180 |
Why?
|
| Liver | 1 | 2022 | 145 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 9 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 145 | 0.170 |
Why?
|
| Genotype | 3 | 2015 | 346 | 0.170 |
Why?
|
| Adult | 4 | 2021 | 7831 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 24 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2019 | 8 | 0.160 |
Why?
|
| Middle Aged | 4 | 2021 | 8923 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2019 | 25 | 0.160 |
Why?
|
| Aminoisobutyric Acids | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cyclopropanes | 1 | 2018 | 9 | 0.150 |
Why?
|
| Proline | 1 | 2018 | 8 | 0.150 |
Why?
|
| Leucine | 1 | 2018 | 10 | 0.150 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 2 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2018 | 9 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 21 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 20 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 102 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2018 | 68 | 0.150 |
Why?
|
| Incidence | 1 | 2020 | 759 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 333 | 0.140 |
Why?
|
| Young Adult | 2 | 2021 | 1994 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Risk Factors | 1 | 2023 | 2302 | 0.140 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 2 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 5 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 17 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 37 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 12 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 47 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 27 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1144 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2024 | 3538 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2015 | 1 | 0.130 |
Why?
|
| Carbamates | 1 | 2015 | 1 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 1 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 24 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2018 | 624 | 0.120 |
Why?
|
| Viral Load | 1 | 2015 | 69 | 0.120 |
Why?
|
| Prognosis | 1 | 2018 | 785 | 0.120 |
Why?
|
| Male | 4 | 2021 | 14772 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 124 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 32 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 108 | 0.120 |
Why?
|
| Consensus | 1 | 2015 | 87 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 312 | 0.110 |
Why?
|
| Ribavirin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2012 | 26 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 38 | 0.090 |
Why?
|
| Time Factors | 1 | 2015 | 1433 | 0.090 |
Why?
|
| Aged | 2 | 2018 | 8997 | 0.070 |
Why?
|
| Pyrroles | 1 | 2022 | 23 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 59 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 18 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 37 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 189 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 33 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 501 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2012 | 45 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 88 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 181 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4777 | 0.020 |
Why?
|